Literature DB >> 8066562

Characterisation of an oxidative response inhibitor produced by Streptococcus pneumoniae.

F E Perry1, C J Elson, T J Mitchell, P W Andrew, J R Catterall.   

Abstract

BACKGROUND: Pneumonia caused by infection with Streptococcus pneumoniae is still a major clinical problem. Reactive oxygen species contribute to the killing of these bacteria by polymorphonuclear leucocytes (PMNs). Defence mechanisms of Str pneumoniae which counter reactive oxygen species are characterised.
METHODS: PMNs were stimulated with phorbol myristate acetate (PMA) in the presence and absence of Str pneumoniae and supernatants from them, and superoxide (O2-) production was measured by the reduction of ferricytochrome c.
RESULTS: Streptococcus pneumoniae, but not Klebsiella pneumoniae or Staphylococcus aureus, inhibited PMA stimulated superoxide production by PMNs. Washed PMNs which had been preincubated with Str pneumoniae autolysis phase supernatants also exhibited depressed H2O2 production in response to PMA. The inhibitory activity was not attributable to non-specific cytotoxicity as assessed by release of the cytoplasmic enzyme lactate dehydrogenase, nor did the supernatants inhibit PMA stimulated degranulation of PMNs. Fractionation of the autolysis phase supernatants revealed inhibitory activity in both the fractions greater than and less than 10 kD. Like pneumolysin the inhibitory activity was heat sensitive. However, both a parent and pneumolysin negative mutant Str pneumoniae, and autolysis phase supernatants from them, inhibited PMN superoxide production. Antisera to pneumolysin failed to abrogate the inhibitory effect of intact Str pneumoniae or autolysis phase supernatants from types 1 or 14 Str pneumoniae.
CONCLUSIONS: The inhibitory effect of Str pneumoniae on the respiratory burst of PMNs is not shared by two other common lung pathogens. The existence of a novel inhibitor of the PMN respiratory burst, distinct from pneumolysin, has been demonstrated. The inhibitor is specific for the respiratory burst and is active both in the logarithmic phase of growth and during autolysis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8066562      PMCID: PMC475056          DOI: 10.1136/thx.49.7.676

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  26 in total

1.  Penicillin resistance in pneumococci.

Authors:  E J Ridgway; K D Allen
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790

2.  Expression of the pneumolysin gene in Escherichia coli: rapid purification and biological properties.

Authors:  T J Mitchell; J A Walker; F K Saunders; P W Andrew; G J Boulnois
Journal:  Biochim Biophys Acta       Date:  1989-01-23

Review 3.  Aspects of pneumococcal infection including bacterial virulence, host response and vaccination.

Authors:  S H Gillespie
Journal:  J Med Microbiol       Date:  1989-04       Impact factor: 2.472

4.  Worldwide increase in pneumococcal antibiotic resistance.

Authors:  K P Klugman; H J Koornhof
Journal:  Lancet       Date:  1989-08-19       Impact factor: 79.321

5.  Increase in resistance to penicillin in pneumococci in Spain.

Authors:  J Casal; A Fenoll; M D Vicioso; R Muñoz
Journal:  Lancet       Date:  1989-04-01       Impact factor: 79.321

Review 6.  Is pneumococcal infection a preventable disease?

Authors:  R Finch
Journal:  J Infect       Date:  1988-09       Impact factor: 6.072

7.  Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae.

Authors:  A M Berry; J Yother; D E Briles; D Hansman; J C Paton
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

8.  Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide.

Authors:  J C Paton; R A Lock; C J Lee; J P Li; A M Berry; T J Mitchell; P W Andrew; D Hansman; G J Boulnois
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

9.  An assessment of the factors contributing to the killing of type 3 Streptococcus pneumoniae by human polymorphonuclear leukocytes in vitro.

Authors:  A L Esposito; C A Clark; W J Poirier
Journal:  APMIS       Date:  1990-02       Impact factor: 3.205

10.  The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

Authors:  E D Shapiro; A T Berg; R Austrian; D Schroeder; V Parcells; A Margolis; R K Adair; J D Clemens
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

View more
  5 in total

Review 1.  Streptococcus pneumoniae.

Authors:  J R Catterall
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

2.  Mucosal administration of flagellin protects mice from Streptococcus pneumoniae lung infection.

Authors:  Natalia Muñoz; Laurye Van Maele; Juan M Marqués; Analía Rial; Jean-Claude Sirard; José A Chabalgoity
Journal:  Infect Immun       Date:  2010-07-19       Impact factor: 3.441

3.  The pneumococcus: host-organism interactions and their implications for immunotherapy and immunoprophylaxis.

Authors:  F E Perry; J R Catterall
Journal:  Thorax       Date:  1994-10       Impact factor: 9.139

4.  Inhibition of the alveolar macrophage oxidative burst by a diffusible component from the surface of the spores of the fungus Aspergillus fumigatus.

Authors:  J Slight; W J Nicholson; C G Mitchell; N Pouilly; P H Beswick; A Seaton; K Donaldson
Journal:  Thorax       Date:  1996-04       Impact factor: 9.139

Review 5.  Neutrophil cell death in response to infection and its relation to coagulation.

Authors:  Toshiaki Iba; Naoyuki Hashiguchi; Isao Nagaoka; Yoko Tabe; Miwa Murai
Journal:  J Intensive Care       Date:  2013-12-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.